Speaker Profile
Ph.D., CEO, Orbits Oncology
Biography
Abraham Lin is the cofounder and CEO of Orbits Oncology, an academic spinout focused on transforming a patients own tumor tissue into actionable insights to personalize cancer treatment. He has harmonized advanced tumor models, live-microscopy imaging, and AI-driven analysis to predict how individual tumors respond to therapy. Trained as an engineer before transitioning into cancer research, Abraham has authored more than 45 scientific publications, holds 4 patents, and received multiple international research awards. His goal has always been to bring more engineering solutions into oncology to benefit researchers and cancer patients. After years of developing academic innovations at the intersection of engineering and oncology, he was compelled to pursue entrepreneurship to translate these advances into real-world solutions and large societal impacts. Today, he applies his extensive cross-disciplinary experience in leading Orbits Oncologys efforts to build scalable, predictive tools that improve cancer care for patients and development of novel therapies.
Talk
Unlocking patient organoids for personalized cancer medicine
Patient-derived organoids are a major breakthrough in 3D tumor lab cultures, but their predictive value remains largely untapped. This talk explores how our AI-powered analysis platform transforms organoids into predictive tools of real-world patient therapy response, unlocking new possibilities for developing novel therapies and personalizing cancer patient care.
AI for Clinical Decision Support Systems Showcase:
Orbits Oncology
Orbits Oncology provides a personalized medicine test that predicts which cancer therapies are most likely to work for each patient, before treatment begins. Using a sample of the patient’s own tumor, we grow lab-tumor models, expose them to medicines from a list of approved options, and identify the most promising therapies for that specific patient.
Session Abstract – PMWC 2026 Silicon Valley
"The PMWC 2026 AI for Clinical Decision Support Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
